secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024143
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Q3 net loss $40.4M on $18.1M goodwill impairment; PRISM4 Phase 3 dosing ongoing
--------------------------------------------------------------------------------

- Net loss $40.4M vs $10.0M in Q3 2021 due to $18.1M goodwill impairment and $11.2M revenue decline from Takeda termination.
- Cash and equivalents $85.3M at Sept. 30, 2022; expected runway into Q2 2024, including sublease inflows.
- Patient dosing underway in PRISM4 Phase 3 trial of CP101 for recurrent C. diff; topline data anticipated H1 2024.
- Howard Franklin appointed Chief Medical Officer; ASD program (FIN-211) suspended; exploring partnerships for IBD candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/0000950170-22-024143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/fnch-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer